Matthew A. Spear

Individualizing management of aggressive fibromatoses

Matthew A. Spear, L. Candace Jennings, Henry J. Mankin et al. · International Journal of Radiation Oncology*Biology*Physics · 1998 · 278 citations

Fibrosis, Antifibrotic Therapy, Aggressive Fibromatoses +6

Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination

Michael Millward, Timothy Price, Amanda Townsend et al. · Investigational New Drugs · 2011 · 148 citations

Vitro Assessments, Oncology, Medicine +6

Efficacy and Safety of P-Bcma-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM)

Tara Gregory, Adam D. Cohen, Caitlin Costello et al. · Blood · 2018 · 104 citations

Phase 1 First-in-Human Trial of the Vascular Disrupting Agent Plinabulin(NPI-2358) in Patients with Solid Tumors or Lymphomas

Monica Mita, Matthew A. Spear, Lorrin Yee et al. · Clinical Cancer Research · 2010 · 102 citations

Phase 1/2 Study of the Safety and Response of P-BCMA-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME) with Novel Therapeutic Strategies

Caitlin Costello, Adam D. Cohen, Krina K. Patel et al. · Blood · 2020 · 76 citations